NCT06907628 A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
| NCT ID | NCT06907628 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-04-02 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 150 participants in total. It began in 2025-04-02 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study. 2. Patients with unresectable recurrent or metastatic solid tumors. 3. There is at least one lesion that could be measured. 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. 5. Adequate organ functions as defined. 6. Life expectancy ≥ 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases. 2. Subjects with other malignancy in five years before the first dose. 3. Patients with tumor-related pain that cannot be controlled as determined. 4. Patients with serious cardiovascular and cerebrovascular diseases. 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion. 6. Patients with severe infections. 7. History of immunodeficiency. 8. History of autoimmune diseases. 9. Active infection. 10. Pregnant or nursing women. 11. Known history of serious allergic reactions to the investigational product or its main ingredients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06907628 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06907628 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06907628 currently recruiting?
Yes, NCT06907628 is actively recruiting participants. Contact the research team at fangfang.peng.fp5@hengrui.com for enrollment information.
Where is the NCT06907628 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06907628 clinical trial?
NCT06907628 is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. The trial plans to enroll 150 participants.